Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Several stocks on the market offer investors the opportunity to capitalize on the rapidly growing field of artificial intelligence (AI). The list includes some of the "Magnificent Seven" stocks, as ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 4.64% at $4.73. The stock's performance was behind the S&P 500's daily gain of 0.03%. At the same time, the Dow lost 0.58%, and ...

These aren't for the faint of heart.

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...